Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1648 1671
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18005332 | COVID-19 Mucosal Antibody Assay | Non-Final OA | NantCell, Inc. |
| 18017165 | METHODS FOR ASSESSING THE SEVERITY AND PROGRESSION OF SARS-COV2 INFECTIONS USING CELL-FREE DNA | Final Rejection | CORNELL UNIVERSITY |
| 17640327 | COMBINATION ANTIVIRAL THERAPY FOR MEASLES | Non-Final OA | Cornell University |
| 18014507 | DETECTING AND QUANTIFYING A VIRAL TARGET NUCLEIC ACID SEQUENCE | Final Rejection | Bar-Ilan University |
| 18252590 | NEW FELINE HERPES VIRUS VACCINE | Non-Final OA | Boehringer Ingelheim Vetmedica GmbH |
| 18300973 | Immunogenic Compositions Against SARS-COV-2 Variants And Their Methods Of Use | Non-Final OA | Inovio Pharmaceuticals, Inc. |
| 17358523 | METHODS OF DETECTING SARS-COV-2, INFLUENZA, AND RSV | Final Rejection | Cepheid |
| 18246117 | COMPOUND FOR INCREASING EFFICACY OF VIRAL VECTORS | Non-Final OA | ABLEVIA BIOTECH GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy